Eliminating need to dilate

Article

Faster technology to be able to screen for diabetic retinopathy is a requirement as the disease is becoming more prevalent.

Faster technology to be able to screen for diabetic retinopathy is a requirement as the disease is becoming more prevalent. A new retinal imaging system has been confirmed to match or outperform fundus cameras in a recent clinical trial.

The DRIVE trial looked at 100 people with diabetes and examined the efficacy of the EasyScan (i-Optics). The performance of the system was assessed head-to-head with a fundus camera in the early diagnosis of diabetic retinopathy.

It was shown that the non-mydriatic confocal SLO technology successfully scanned all 100 patients without pharmacological dilation. Additionally, a large portion of the study group could be imaged in under 3 minutes. The results of this trial will be featured in ARVO and will add to the results of an earlier trial of the system’s imaging performance.

One of the first doctors to use the system in the US Dr Steven Squillace gave his opinion on the system. "I've worked with SLO technology for retinal evaluation over 10 years ago as part of a group practice. We saw the benefit of undilated fundus images, but also the drawback… When I heard there was a smaller version being launched, I thought it could be what I needed."

Dr Squillace has used the technology on over 100 patients and now states that he uses it exclusively for routine check ups.

If you would like to read more about the EasyScan the full article can be found in the May print issue of OTEurope.

Recent Videos
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
3 experts are featured in this series.
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Sunita Radhakrishnan, MD, an associate at the Glaucoma Center of San Francisco, speaks at the annual Glaucoma 360 meeting about electrical neurostimulation.
3 experts are featured in this series.
3 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.